Der Internist

, Volume 50, Issue 5, pp 617–626 | Cite as

Nobelpreis für die Impfung gegen Zervixkrebs

Aktuelle Daten- und Leitlinienlage
Arzneimitteltherapie

Zusammenfassung

Harald zur Hausen erhielt 2008 den Nobelpreis für Medizin für seine grundlegenden Arbeiten zu humanen Papillomaviren (HPV) und ihrer Assoziation mit anogenitalen Erkrankungen. Auf Basis seiner Arbeiten wurden hochwirksame prophylaktische HPV-Impfstoffe entwickelt. Klinische Studien zeigten fast 100% Serokonversion und hervorragende Sicherheitsdaten sowie eine über 96%ige Wirksamkeit gegen persistierende Infektionen und prämaligne Dysplasien, die durch HPV-Typen hervorgerufen werden, die vom Impfstoff abgedeckt werden. Aufgrund der überzeugenden Studiendatenlage der Phase-II- und -III-Studien wurde die Einführung der Impfung durch Zulassungsbehörden und sachkundige Gremien empfohlen. Die Formulierung und Verfügbarkeit hochgradiger Leitlinien und evidenzbasierter Empfehlungen sollte die Einführung der Vakzine und flächendeckende Impfung unterstützen.

Schlüsselwörter

Zervixkarzinom Gebärmutterhalskrebs HPV-Impfstoffe Impfempfehlung 

Nobel price for vaccination against cervical cancer: Current data and guidelines

Abstract

Harald zur Hausen received the Nobel price for Medicine in 2008 for his seminal research on human papilloma viruses and their association with anogenital diseases. On the basis of his work highly effective prophylactic vaccines have been developed. Clinical studies have shown nearly 100% seroconversion and an excellent safety profile as well as greater than 96% efficacy against HPV infection and premalignant dysplasia, induced by HPV types covered by the vaccine. Due to the convincing data of phase II and III clinical trials the introduction of HPV vaccination was recommended by health authorities and scientific committees in Germany. The development and availability of guidelines and evidence-based recommendations should support the introduction of the vaccine and widespread vaccination.

Keywords

Cervical cancer Human papilloma viruses HPV-vaccines Recommendation for vaccination 

Literatur

  1. 1.
    Ault KA (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369: 1861–1868PubMedCrossRefGoogle Scholar
  2. 2.
    Booy FP, Roden RB, Greenstone HL et al. (1998) Two antibodies that neutralize papillomavirus by different mechanisms show distinct binding patterns at 13 A resolution. J Mol Biol 281: 95–106PubMedCrossRefGoogle Scholar
  3. 3.
    Boshart M, Gissmann L, Ikenberg H et al. (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO J 3: 1151–1157PubMedGoogle Scholar
  4. 4.
    David MP, Van Herck K, Hardt K et al. (2009) Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol [Epub ahead of print]Google Scholar
  5. 5.
    Durst M, Gissmann L, Ikenberg H, Zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci U S A 80: 3812–3815PubMedCrossRefGoogle Scholar
  6. 6.
    FUTURE II (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927CrossRefGoogle Scholar
  7. 7.
    Garland SM, Hernandez-Avila M, Wheeler CM et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928–1943PubMedCrossRefGoogle Scholar
  8. 8.
    Garland SM, Steben M, Hernandez-Avila M et al. (2007) Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14: 792–795PubMedCrossRefGoogle Scholar
  9. 9.
    Giannini SL, Hanon E, Moris P et al. (2006) Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24: 5937–5949PubMedCrossRefGoogle Scholar
  10. 10.
    Harper DM, Franco EL, Wheeler C et al. (2004) Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364: 1757–1765PubMedCrossRefGoogle Scholar
  11. 11.
    Harper DM, Franco EL, Wheeler CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367: 1247–1255PubMedCrossRefGoogle Scholar
  12. 12.
    Joura EA, Leodolter S, Hernandez-Avila M et al. (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369: 1693–1702PubMedCrossRefGoogle Scholar
  13. 13.
    Khan MJ, Castle PE, Lorincz AT et al. (2005) The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 97: 1072–1079PubMedCrossRefGoogle Scholar
  14. 14.
    Kirnbauer R, Booy F, Cheng N et al. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89: 12180–12184PubMedCrossRefGoogle Scholar
  15. 15.
    Koutsky L (1997) Epidemiology of genital human papillomavirus infection. Am J Med 102: 3–8PubMedCrossRefGoogle Scholar
  16. 16.
    Luther-Übersetzung (1545) Die Bibel, 5. Buch Mose. Kap. 28, Vers 27Google Scholar
  17. 17.
    McCredie MR, Sharples KJ, Paul C et al. (2008) Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 9: 425–434PubMedCrossRefGoogle Scholar
  18. 18.
    Paavonen J, Jenkins D, Bosch FX et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161–2170PubMedCrossRefGoogle Scholar
  19. 19.
    Pathirana D, für das HPV Management Forum (2008) S3-Leitlinie zur Impfprävention HPV-assoziierter Neoplasien. J Chemother 17: 120–171Google Scholar
  20. 20.
    Reisinger KS, Block SL, Lazcano-Ponce E et al. (2007) Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26: 201–209PubMedCrossRefGoogle Scholar
  21. 21.
    Robert Koch-Institut (2007) Mittteilung der Ständigen Impfkommission (STIKO) am Robert-Koch-Institut. Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren – Empfehlung und Begründung. Epidemiol Bull 12: 97–103Google Scholar
  22. 22.
    Schiller JT, Castellsague X, Villa LL, Hildesheim A (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 26 (Suppl): K53–K61PubMedCrossRefGoogle Scholar
  23. 23.
    Schreckenberger C, Kaufmann AM, Schneider A (2007) Implementation of HPV vaccination in Germany. Dtsch Med Wochenschr 132: 2221–2224PubMedCrossRefGoogle Scholar
  24. 24.
    Siegrist CA, Lewis EM, Eskola J et al. (2007) Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J 26: 979–984PubMedCrossRefGoogle Scholar
  25. 25.
    Smith JF, Brownlow M, Brown M et al. (2007) Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 3: 109–115PubMedGoogle Scholar
  26. 26.
    Villa LL, Ault KA, Giuliano AR et al. (2006) Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24: 5571–5583PubMedCrossRefGoogle Scholar
  27. 27.
    Villa LL, Costa RL, Petta CA et al. (2006) High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95: 1459–1466PubMedCrossRefGoogle Scholar
  28. 28.
    Vonka V, Kanka J, Hirsch I et al. (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrolment. Int J Cancer 33: 61–66PubMedCrossRefGoogle Scholar
  29. 29.
    Vonka V, Kanka J, Jelinek J et al. (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer 33: 49–60PubMedCrossRefGoogle Scholar
  30. 30.
    Wheeler CM, Bautista OM, Tomassini JE et al. (2008) Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine 26: 686–696PubMedCrossRefGoogle Scholar
  31. 31.
    Zur Hausen H (1976) Condylomata acuminata and human genital cancer. Cancer Res 36: 794Google Scholar
  32. 32.
    Zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342–350CrossRefGoogle Scholar
  33. 33.
    Zur Hausen H (2009) Papillomaviruses in the causation of human cancers – a brief historical account. Virology 384: 260–265CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2009

Authors and Affiliations

  1. 1.Gynäkologische Tumorimmunologie, Klinik für GynäkologieCharité, Campus Benjamin FranklinBerlinDeutschland

Personalised recommendations